IndonesiaTuberculosis profile
Population  2016 261 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 110 (75–150) 42 (29–58)
Mortality (HIV+TB only) 13 (6.2–23) 5.1 (2.4–8.7)
Incidence  (includes HIV+TB) 1 020 (660–1 460) 391 (253–558)
Incidence (HIV+TB only) 45 (21–78) 17 (8–30)
Incidence (MDR/RR-TB)** 32 (19–45) 12 (7.3–17)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 28 (17–39) 294 (179–410) 323 (196–449)
Males 32 (19–44) 666 (405–928) 698 (424–972)
Total 60 (36–83) 961 (584–1 340) 1 020 (660–1 460)
TB case notifications, 2016  
Total cases notified 360 565
Total new and relapse 358 608
          - % tested with rapid diagnostics at time of diagnosis <1%
          - % with known HIV status 14%
          - % pulmonary 92%
          - % bacteriologically confirmed among pulmonary 59%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 35% (25–54)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.13 (0.07–0.19)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 4 330 9%
          - on antiretroviral therapy 1 228 28%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  11 000
(8 800–13 000)
Estimated % of TB cases with MDR/RR-TB 2.8% (2.2–3.5) 16% (10–20)  
% notified tested for rifampicin resistance 2% 176% 26 973
MDR/RR-TB cases tested for resistance to second-line drugs   1 060
Laboratory-confirmed cases MDR/RR-TB: 2 720, XDR-TB: 37
Patients started on treatment **** MDR/RR-TB: 1 879, XDR-TB: 52
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 85% 331 703
Previously treated cases, excluding relapse, registered in 2015 67% 1 859
HIV-positive TB cases registered in 2015 60% 3 634
MDR/RR-TB cases started on second-line treatment in 2014 51% 1 271
XDR-TB cases started on second-line treatment in 2014 13% 30
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 2%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
1.5% (1.3–1.6)
TB financing, 2017  
National TB budget (US$ millions) 185
Funding source: 29% domestic, 18% international, 53% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-18 Data: www.who.int/tb/data